A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00160511|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 26, 2013
|Condition or disease||Intervention/treatment||Phase|
|Neuralgia, Postherpetic||Drug: Levetiracetam||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||170 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-blind, Randomized, Placebo-controlled, Parallel-group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||August 2005|
|Actual Study Completion Date :||September 2005|
- Assess efficacy of levetiracetam in the treatment of Post Herpetic Neuralgia by measuring the absolute change in the average weekly Pain Intensity Scale (PIS).
- Assess the efficacy, safety and tolerability of levetiracetam in the treatment of Post Herpetic Neuralgia; Reduction in the mean PIS over the last week of the evaluation period compared to the baseline period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160511
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|